VT-5006 oral therapy advances into Phase 1b testing for Parkinson’s disease

The first participant has been dosed in Vertero Therapeutics’ Phase 1b clinical trial testing VT-5006, an investigational, gut-directed oral small molecule being developed for Parkinson’s disease.

The Phase 1b clinical trial (NCT07310264) is still recruiting adults ages 40-80 with early- or moderate-stage Parkinson’s who were diagnosed within the past 10 years, at one site in the Netherlands. This follows the completion of the first part of the trial in healthy volunteers, which found no significant safety or tolerability signals, according to the company.

“Advancing into the Parkinson’s population is an important milestone that will provide some early clarity on the therapeutic potential of VT-5006,” Becca Senter, PhD, chief scientific officer of Vertero, said in a company press release. “Our ultimate goal is to advance the standard of care and deliver a transformative, disease-modifying option that the Parkinson’s community has long awaited.”

Parkinson’s disease is marked by the progressive loss of dopaminergic neurons, the nerve cells that produce dopamine, a chemical messenger essential for movement. The accumulation of toxic clumps of misfolded proteins, particularly alpha-synuclein, is thought to be one key driver of this nerve cell damage.

Recommended Reading

May 14, 2026 News by Michela Luciano, PhD

Vyalev eases motor, nonmotor symptoms in advanced Parkinson’s

Therapy targets gut pathway linked to Parkinson’s

Several studies have suggested that, in at least some people, Parkinson’s-related changes may start in the enteric nervous system, the network of nerves embedded in the gut wall. This idea is supported by findings of alpha-synuclein clumps in the gut of people with Parkinson’s and evidence that these protein clumps may spread from the intestine to the brain.

VT-5006 is a first-in-class, gut-selective small molecule designed to target CsgA, a microbial amyloid used by bacteria to anchor to the gastrointestinal wall. According to Vertero, CsgA helps drive alpha-synuclein aggregation and inflammation that can spread to the brain. By targeting CsgA, VT-5006 aims to reduce protein aggregation and associated inflammation, potentially easing symptoms and slowing disease progression.

“By targeting these early upstream mechanisms, Vertero is pursuing an innovative strategy that has the potential not only to address symptoms, but also fundamentally influence the underlying biological drivers of Parkinson’s disease,” said Bastiaan Bloem, MD, PhD, professor of movement disorder neurology and director of the Center of Expertise for PD at Radboud University Medical Centre, and a Vertero Scientific Advisory Board member.

In preclinical research, VT-5006 reduced brain pathology and inflammation, improved motor function, and slowed disease progression, according to Vertero.

The Phase 1 study was initiated last year in healthy volunteers, who received VT-5006 or a placebo as a single dose or once daily for seven days.

The trial will now assess the treatment’s safety, tolerability, pharmacokinetics, target engagement, and exploratory pharmacodynamic measures in people with Parkinson’s who are CsgA positive.

It will initially enroll 24 participants, who will be randomly assigned to receive VT-5006 at a low or high dose or placebo daily for 28 days.

“As the program advances into evaluation in patients with [Parkinson’s], this trial will provide important translational insights into addressing the underlying mechanism, which could ultimately have a tangible impact on the long-term outlook for this disease,” Bloem added.